Oxandrolone kidney function

Optimal regimen and place in therapy have not been defined; doses ranging from 300 to 2,500 units/kg/dose IV have been given daily or every other day for a short duration after birth. In a study of 167 term neonates with moderate to severe HIE, the use of erythropoietin (300 or 500 units/kg/dose every other day for 2 weeks beginning less than 48 hours after birth) resulted in improved neurological outcomes in patients with moderate (but not severe) HIE compared to conventional treatment (no erythropoietin). At 18 months of age, fewer patients in the erythropoietin group had experienced death or moderate/severe disability compared to the control group (% vs. %, respectively; p = ); neonates in the erythropoietin group also had fewer hospitalizations during the study period. No difference was found between the erythropoietin doses. In a prospective case-control study, the administration of erythropoietin 2,500 units/kg/dose subcutaneously for 5 days to neonates with mild/moderate HIE (n = 15) was associated with fewer neurologic and developmental abnormalities at 6 months of age compared to conventional therapy (no erythropoietin; n = 15). Erythropoietin was well tolerated.

Androgens are responsible for the growth spurt of adolescence and for the eventual termination of linear growth, which is brought about by fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of growth process. Androgens have been reported to stimulate the production of red blood cells by enhancing the production of erythropoeitic stimulating factor. During exogenous administration of androgens,  endogenous testosterone  release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH).

Duchaine would inevitably pay dearly for his research and involvement in the performance enhancing world; twice he would be charged, arrested and sentenced to prison for his involvement but this would appear to never phase this man’s desire for knowledge and understanding of the anabolic world; so much so that the anabolic using world owes much of what it knows to the late Duchaine. Unfortunately Duchaine’s life was short lived as this living breathing steroid encyclopedia lost his life in January of 2000 due to kidney failure at the age of 47. Upon his death it was determined Duchaine’s kidney failure was caused by hereditary polycystic kidney disease and with it the world lost one of the few who truly understood performance enhancing drugs.

Oxandrolone kidney function

oxandrolone kidney function


oxandrolone kidney functionoxandrolone kidney functionoxandrolone kidney functionoxandrolone kidney functionoxandrolone kidney function